SML3511
S-217622
≥98% (HPLC)
别名:
(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-Triazine-2,4(1H,3H)-dione, Ensitrelvir, S 217622
产品名称
S-217622, ≥98% (HPLC)
InChI
1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)
InChI key
QMPBBNUOBOFBFS-UHFFFAOYSA-N
SMILES string
O=C1N/C(N(C(N1CC2=NN(C=N2)C)=O)CC3=CC(F)=C(F)C=C3F)=N\C4=CC5=CN(N=C5C=C4Cl)C
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Orally available potent and selective noncovalent and nonpeptidic inhibitor of SARS-CoV-2 3C-like protease (3CLpro, or Mpro)
S-217622 is an orally available potent and selective noncovalent and nonpeptidic inhibitor of SARS-CoV-2 3C-like protease (3CLpro, or Mpro) that exhibits antiviral activity in vitro against varies variants of SARS-CoV-2 and other coronaviruses. S-217622 potently inhibits intrapulmonary replication of SARS-CoV-2 in mice.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Journal of medicinal chemistry, 65(9), 6499-6512 (2022)
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2
Tyndall JDA
Journal of Medicinal Chemistry, 65(9), 6496-6498 (2022)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持